Methylprednisolone-induced hepatotoxicity in a 16-year-old girl with multiple sclerosis

Rotondo, Eleonora; Graziosi, Alessandro; Stefano, Vincenzo Di; Mohn, Angelika

doi:10.1136/bcr-2018-226687

Cited by 5 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hepatic dysfunction, accompanied by nausea and vomiting, is a relatively frequent side effect of AZA. However, these symptoms can also occur with TFL or even iv methylprednisolone [ 26 , 27 ]. These results are consistent with the Cochrane review by Casetta et al [ 4 ] and emphasize that AZA is a safe alternative with proper monitoring.…”

Section: Discussionmentioning

confidence: 99%

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

Agrawal,

Srivastava,

Bhatia

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

Azathioprine (AZA) has demonstrated efficacy in multiple randomized control trials (RCTs) for Relapsing-Remitting Multiple Sclerosis (RRMS). However, we still need comparative real-world data with other first-line disease-modifying therapies (DMTs). We aimed to assess AZA’s effectiveness regarding relapses, disability progression, time to the first relapse, magnetic resonance imaging (MRI) activity, and safety compared with other approved first-line DMTs in an Indian population in a real-world setting. We conducted a single-center prospective study of treatment-naive RRMS patients between 2017 and 2019. We evaluated the effects of AZA and other approved DMTs on clinical and radiological measures. Among 192 eligible patients (F:M ratio 2.84:1), 68 patients (35.4%) were on AZA, 68 patients (35.4%) were on dimethyl fumarate (DMF), 32 patients (16.7%) on interferon (IFN beta-1a), and 16 patients (8.3%) on teriflunomide (TFL). Four treatment groups were comparable: AZA v/s DMF v/s TFL v/s IFN beta-1a. In primary outcomes, there was no significant difference between the groups in terms of change in the Expanded Disability Status Scale (EDSS) score at three months (p-value = 0.169), six months (p-value = 0.303), 12 months (p-value = 0.082), and 24 months (p-value = 0.639), the number of relapses (p-value = 0.229), and time to the first relapse (p-value > 0.05 in all groups). In the secondary outcome, there was no significant difference between the treatment groups on serial MRI parameters used according to “Magnetic Resonance Imaging in Multiple Sclerosis” (MAGNIMS) 2016 criteria (p-value > 0.05). In safety outcomes, leukopenia was significantly more common in the AZA group (p-value = 0.025), flu-like symptoms (p-value = 0.0001), and injection site reactions (p-value = 0.035) were significantly more common in the IFN beta-1a group. Our study suggests AZA is as effective as other approved DMTs and a good alternative as a first-line treatment for multiple sclerosis’s clinical and radiological activity in real-world settings on short follow-up. Based on these results, more randomized controlled trials of AZA v/s DMF or other DMTs are needed for more robust outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

Agrawal,

Srivastava,

Bhatia

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…ЛПП, ассоциированные с метилпреднизолоном, описаны в литературе в основном у пациентов с демиелинизирующими заболеваниями [5][6][7][8] и офтальмопатией Грейвса, вероятно, ввиду более частого употребления пульс-терапии высокими дозами метилпреднизолона. Исследование V. Nociti и соавт.…”

Section: дискуссияunclassified

Drug-induced liver injury after high-dose methylprednisolone: Clinical case

Shumskaya

Nefedova

Akhmedzyanova

et al. 2022

SJCEM

View full text Add to dashboard Cite

We present a clinical case of acute hepatitis confirmed by liver biopsy. A 24-year-old patient underwent pulse therapy with methylprednisolone due to the onset of multiple sclerosis. The liver enzyme values were within the normal range 15 days later. Blood tests revealed the development of cytolysis syndrome during an unrelated medical examination two months later. Obvious causes of hepatitis were excluded, and liver biopsy was performed to verify the diagnosis. The biopsy showed a picture of acute hepatitis with high histological activity and development of submassive necrosis. The situation was interpreted as drug-induced liver injury after pulse therapy with methylprednisolone. Oral prednisone therapy was prescribed, and the inflammation and liver injury were reverted. The presented clinical case highlights the importance of follow-up of patients receiving high doses of methylprednisolone.

show abstract

“…A total number of 50 cases presented in 7 case series and 24 single case reports were retrieved from 2000 to 2018, carefully reviewed and analyzed in this study (Tables 1 and 2). 4–34…”

Section: Case Seriesmentioning

confidence: 99%

Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review

et al. 2019

View full text Add to dashboard Cite

Background and Objectives Corticosteroids are often empirically used to treat idiosyncratic hepatotoxicity with severe features. Interestingly, intravenous methylprednisolone (MP) is increasingly being recognized as being responsible for liver injury. We aimed to characterize MP-induced liver injury by analyzing demographical, clinical, laboratory and outcome data of three MP-induced hepatotoxicity cases and compared this information with that of previously published cases. Case series Three females with multiple sclerosis (MS) were treated intravenously with MP, mean daily dose 767 mg. Liver damage occurred 2 to 6 weeks after exposure. Severity was mild to moderate. Two patients suffered positive rechallenge. Literature review We identified 50 published cases of MP hepatotoxicity. Most of these cases were female (86%) and main treatment indications were MS (29 cases) and Graves' ophthalmopathy (13 cases). Hepatocellular damage predominated and mean time to onset was 6 weeks. Four patients died and rechallenge occurred in 19 cases. Conclusion MP pulses can induce severe liver injury, often with an autoimmune phenotype, particularly in patients with MS and Graves' ophthalmopathy. Consequently, these patient groups should have liver tests monitored when treated with MP to provide safer patient care.

show abstract

Methylprednisolone-induced hepatotoxicity in a 16-year-old girl with multiple sclerosis

Cited by 5 publications

References 50 publications

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study

Drug-induced liver injury after high-dose methylprednisolone: Clinical case

Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review

Contact Info

Product

Resources

About